Q2 2026 Healthcare M&A Review
- 4 hours ago
- 1 min read
We are pleased to release our review of M&A, private equity and venture capital activity across the UK healthcare sector in Q2 of 2026.
Our report, which can be downloaded below, highlights the most active sub-sectors, along with a month-by-month summary of the key deals across the market.
Q2 2026 Healthcare M&A Review Summary
Deal Volumes
Q2 activity remained subdued as economic uncertainty and a more challenging market tempered deal completions.
We may see increased activity in late 2026 / early-2027 due to concerns of owner-managed businesses around a potential uplift in CGT rates due to political changes.
Sub-Sector Activity
Elderly and specialist care led activity, as investors and acquirers move towards non-cyclical demand and resilient cashflows, in addition to lower exposure to AI disruption.
Medical equipment attracted further interest from PE-backed consolidators, particularly in consumables and single-use devices.
Digital Health deal activity focused on primary care software, care management platforms and workflow technology.
Veterinary clinic deal flow continued to increase, driven by emerging platforms such as Vetthing and Kin Vet.
Private Equity Involvement
PE was involved (either directly or indirectly) in over 60% of tracked transactions. Activity was more evenly spread across sectors, with focus on digital health, medical equipment, veterinary and specialist care.
Q2 saw new platforms for Bay Tree (Medicare Insourcing), Amulet Capital (TFP Fertility), TPG (Optum UK), Charterhouse (Animalcare Group), STAR Capital (Glenholme), Sofina (Creature Comforts) and Chariot Capital (Laser Clinics UK).